Zealand Pharma AS (CHIX:ZEALC) Beta: 0.2488 (As of Jun. 26, 2026)


CHIX:ZEALC Zealand Pharma AS CHIX:ZEALC
58 GF Score
Price kr278.70
GF Value kr12,477.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Beta?

Zealand Pharma AS CHIX:ZEALC 58 Beta is 0.2488 as of Jun. 26, 2026. GuruFocus rates CHIX:ZEALC with a GF Score™ of 58/100 and a GF Value™ of kr12,477.77 (Possible Value Trap). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Zealand Pharma AS's Beta is 0.2488.


Zealand Pharma AS  (CHIX:ZEALc) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Zealand Pharma AS Beta Related Terms


Zealand Pharma AS Beta Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Beta Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -2.89 -2.81 -0.01

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 -2.64 -0.17 -0.01 0.15

CHIX:ZEALC vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Beta distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Beta falls into.


CHIX:ZEALC
58GF Score
Zealand Pharma AS CHIX:ZEALC
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2488 mean?
Zealand Pharma AS (CHIX:ZEALC) has a Beta of 0.2488 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Beta too high?
Zealand Pharma AS's current Beta is 0.2488. Overall, Zealand Pharma AS has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Beta compare to VRTX and REGN?
Zealand Pharma AS's Beta of 0.2488 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zealand Pharma AS and its competitors. Zealand Pharma AS's current Beta is 0.2488. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (CHIX:ZEALC) is currently considered Possible Value Trap. The stock's GF Value™ is kr12,477.77, compared to a current price of kr278.70 — trading 97.8% below its estimated fair value. The current Beta is 0.2488. Zealand Pharma AS's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Zealand Pharma AS (CHIX:ZEALC), the current Beta is 0.2488 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (CHIX:ZEALC) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of kr278.70 is trading 97.8% below its estimated GF Value™ of kr12,477.77. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for CHIX:ZEALC:

  • Beta: 0.2488
  • GF Value™: kr12,477.77 vs. price of kr278.70 (97.8% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the CHIX:ZEALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
58GF Score

Get the complete analysis for CHIX:ZEALC

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr278.70
Price
kr12,477.77
GF Value